Who are Xibrom's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Loqoa, Nevanac, Xapit, Valecoxib, Mobic, (+)-Ketoprofen.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bromfenac.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Xibrom — Competitive Intelligence Brief

Xibrom (BROMFENAC) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal Anti-inflammatory Drug. Area: Ophthalmology.

marketed Nonsteroidal Anti-inflammatory Drug Prostaglandin G/H synthase 2 Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Xibrom (BROMFENAC) — Bausch Health. Xibrom works by blocking the production of prostaglandins, which are hormone-like substances that cause pain and inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Xibrom TARGET	BROMFENAC	Bausch Health	marketed	Nonsteroidal Anti-inflammatory Drug	Prostaglandin G/H synthase 2	2005-01-01
Loqoa	ESFLURBIPROFEN	Taisho Pharmaceutical Co., Ltd.	marketed		Prostaglandin G/H synthase 2	2015-01-01
Nevanac	NEPAFENAC	Harrow Health	marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	Prostaglandin G/H synthase 2	2005-01-01
Xapit	PARECOXIB		marketed	parecoxib	Prostaglandin G/H synthase 2	2002-01-01
Valecoxib	VALDECOXIB		marketed	valdecoxib	Prostaglandin G/H synthase 2	2001-01-01
Mobic	MELOXICAM	Boehringer Ingelheim	marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	Prostaglandin G/H synthase 2	2000-01-01
(+)-Ketoprofen	DEXKETOPROFEN		marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2	1994-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2030-05-26 — Mobic · 10709713 · Method of Use · US
2030-05-26 — Mobic · 9974746 · Formulation · US
2030-05-26 — Mobic · 11253478 · Formulation · US
2030-08-31 — Mobic · 8545879 · Formulation · US
2033-03-31 — Mobic · 9526734 · Formulation · US
2035-03-31 — Mobic · 9808468 · Method of Use · US
2035-03-31 — Mobic · 9649318 · Formulation · US
2039-03-08 — Mobic · 11458145 · Method of Use · US
2039-03-08 — Mobic · 10881663 · Method of Use · US
2040-07-19 — Mobic · 12059423 · Compound · US
2041-07-31 — Mobic · 12263176 · Formulation · US

Sponsor landscape (Nonsteroidal Anti-inflammatory Drug class)

· 5 drugs in this class
Bausch Health · 1 drug in this class
Hisamitsu Pharmaceutical Co., Inc · 1 drug in this class
Pfizer · 1 drug in this class
Pharmaco · 1 drug in this class
Sun Yat-sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Xibrom — Competitive Intelligence Brief. https://druglandscape.com/ci/bromfenac. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab